Costy Mattar
Cardiovascular Disease · Hutchinson, KSNPI 1780860411
Payments from drug & device makers
Across 404 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abbott$2K
- Novartis$467
- E.r. Squibb & Sons, L.L.C.$418
- Merck$370
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$362
- plus $3K from 31 others
What the payments were for
- Travel & lodging$3,50932%
- Food & beverage$7,34366%
- Education$1982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 87 | $4,547 |
| Abbott | 75 | $2,324 |
| Novartis | 30 | $467 |
| E.r. Squibb & Sons, L.L.C. | 23 | $418 |
| Merck | 23 | $370 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $362 |
| AstraZeneca | 22 | $319 |
| Amgen | 17 | $293 |
| Pfizer | 20 | $254 |
| Johnson & Johnson | 21 | $224 |
| Astellas Pharma US Inc | 4 | $223 |
| Daiichi Sankyo Inc. | 6 | $150 |
| Actelion Pharmaceuticals US, Inc. | 8 | $108 |
| Inari Medical, Inc. | 2 | $99 |
| Boehringer Ingelheim | 5 | $95 |
| Lantheus Medical Imaging, Inc. | 4 | $87 |
| Cvrx, Inc. | 6 | $86 |
| Shockwave Medical, Inc | 1 | $77 |
| Abiomed | 2 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Stryker | 1 | $48 |
| Penumbra, Inc. | 2 | $48 |
| Boston Scientific | 3 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Surmodics, Inc. | 2 | $25 |
| United Therapeutics Corporation | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Angiodynamics, Inc. | 1 | $18 |
| Canon Medical Systems USA, Inc. | 1 | $17 |
| Coala Life Inc | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,050 in reported general payments places this provider in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 734 | $561,876 |
| XareltoRivaroxaban | 180 | $156,862 |
| EntrestoSacubitril/Valsartan | 43 | $35,310 |
| BrilintaTicagrelor | 19 | $21,296 |
| Repatha SureclickEvolocumab | 26 | $21,038 |
| JardianceEmpagliflozin | 19 | $13,352 |
| Praluent PenAlirocumab | 17 | $10,924 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 48 | $8,792 |
| Flecainide Acetate | 220 | $8,151 |
| ClopidogrelClopidogrel Bisulfate | 760 | $6,661 |
| Midodrine Hcl | 23 | $5,122 |
| Atorvastatin Calcium | 735 | $4,844 |
| Metoprolol Tartrate | 1,001 | $4,438 |
| Metoprolol Succinate | 400 | $3,960 |
| Amiodarone Hcl | 423 | $3,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $254 | $561,876734 claims |
| Johnson & JohnsonXarelto | $224 | $156,862180 claims |
| NovartisEntresto | $467 | $35,31043 claims |
| AstraZenecaBrilinta | $319 | $21,29619 claims |
| Boehringer IngelheimJardiance | $95 | $13,35219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Hutchinson
- Michael HagleyHutchinson$7K
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Stephen BloomOverland Park$766K
- Vasvi SinghOverland Park$436K
- Lloyd StahlOverland Park$275K
- Thomas AshcomWichita$193K
- Chen Hoe ChowTopeka$187K
- Joseph GalichiaWichita$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.